Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01222)
Name
Lorlatinib
Synonyms    Click to Show/Hide the Synonyms of This API
Lorlatinib; 1454846-35-5; PF-06463922; Loratinib; Lorbrena; PF06463922; UNII-OSP71S83EU; PF 06463922; OSP71S83EU; CHEMBL3286830; C21H19FN6O2; Lorlatinib (PF-06463922); 1454846-35-5 (free base); (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; MFCD28144520; (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile.; (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile; 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; 2H-4,8-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; lorlatinibum; Lorviqua; Lorlatinib,PF-06463922; 4cli; 4clj; Lorbrena (TN); Lorlatinib [USAN:INN]; PFE-PKIS 10; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; PF-06463922 Lorlatinib; SCHEMBL15261807; AMY3295; EX-A828; CHEBI:143117; (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-H][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile; BCP10287; 2641AH; BDBM50018830; NSC780108; NSC800990; s7536; ZINC98208524; AKOS027250753; CCG-268718; CS-3983; DB12130; NSC-780108; NSC-800990; NCGC00386417-02; NCGC00386417-13; 7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; AC-30881; HY-12215; A14207; D11012; J-690185; Q27285820; (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
Clinical Status
Approved
PubChem CID
71731823
Formula
C21H19FN6O2
Canonical SMILES
C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C
InChI
1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChIKey
IIXWYSCJSQVBQM-LLVKDONJSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=71731823"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 406.4 Topological Polar Surface Area 110
XlogP 1.5 Complexity 700
Heavy Atom Count 30 Rotatable Bond Count 0
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Full List of Drug Formulations (DFMs) Containing This API
          Lorlatinib 100 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose; Dibasic Calcium Phosphate Anhydrous; Sodium Starch Glycolate; Magnesium Stearate; Hydroxypropyl Methylcellulose (Hpmc) 2910/Hypromellose; Lactose Monohydrate; Macrogol/Polyethylene Glycol (Peg) 3350; Triacetin; Titanium Dioxide; Ferrosoferric Oxide/Black Iron Oxide; Iron Oxide Red
                   Dosage Form Tablet
                   Company Pfizer Laboratories Div Pfizer
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [1]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Calcium hydrogenphosphate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Polyethylene glycol 3350 DIG Info Albendazole monooxygenase (Protein expression upregulation) [2]
          Lorlatinib 25 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose; Dibasic Calcium Phosphate Anhydrous; Sodium Starch Glycolate; Magnesium Stearate; Hydroxypropyl Methylcellulose (Hpmc) 2910/Hypromellose; Lactose Monohydrate; Macrogol/Polyethylene Glycol (Peg) 3350; Triacetin; Titanium Dioxide; Ferrosoferric Oxide/Black Iron Oxide; Iron Oxide Red
                   Dosage Form Tablet
                   Company Pfizer Laboratories Div Pfizer
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hypromellose DIG Info Cytochrome P450 3A5 (IC50 = 19.4 uM) [1]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Calcium hydrogenphosphate DIG Info Albendazole monooxygenase (Protein expression downregulation) [2]
Polyethylene glycol 3350 DIG Info Albendazole monooxygenase (Protein expression upregulation) [2]
References
1 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
2 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.